1. Scrip
  2. >>Business
  3. >>Earnings

Bristol’s New Launches Hit Reality As New Product Portfolio Forecast Is Revised

 
• By Mary Jo Laffler

With slower than expected sales of some newer products, Bristol lowered mid-term guidance for its new product portfolio and extended the timeline for reaching the goal to 2026. 

• Source: Shutterstock

Bristol Myers Squibb Company has a lot riding on several new product launches that are expected to help the company through a challenging period of patent expirations, but the company’s third quarter sales and earnings report on 26 October revealed that some cracks in the plan are beginning to surface.

The primary stressors are generic competition to Revlimid (lenalidomide), a step-down in Eliquis (apixaban) pricing due to it being one of the drugs selected for the first round of Medicare price

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.